Equities

Daiken Medical Co Ltd

7775:TYO

Daiken Medical Co Ltd

Actions
Health CareMedical Equipment and Services
  • Price (JPY)553.00
  • Today's Change1.00 / 0.18%
  • Shares traded2.30k
  • 1 Year change+8.64%
  • Beta0.5269
Data delayed at least 20 minutes, as of May 22 2024 02:03 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

DAIKEN MEDICAL CO., LTD. is a Japan-based company mainly engaged in planning, development, manufacturing and sales of anesthesia and hospital infection control related products. The Company’s products are divided into five groups. The suction device related products include Fit Fix suction container system and Coopdech QinPot. The syrinjector related products include syrinjector, balloonjector, patient control analgesia (PCA) devices and other pressure infusion instruments. The electric pump related products include syringe pumps and infusion pumps. The medical hand washing machine related products include SteriKeep II and Wipell. The other products include bronchial blocker tube, breath warm and others.

  • Revenue in JPY (TTM)9.75bn
  • Net income in JPY988.60m
  • Incorporated1968
  • Employees188.00
  • Location
    Daiken Medical Co Ltd2-6-2, AyuminoIZUMI-SHI 594-1157JapanJPN
  • Phone+81 725303150
  • Fax+81 662319902
  • Websitehttps://daiken-iki.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Create Medic Co Ltd12.69bn83.34m9.29bn962.00104.670.572413.450.73189.189.181,395.571,678.910.66781.734.3913,193,190.000.43853.000.51453.5343.6845.360.65674.602.98--0.050363.222.103.11-68.06-25.530.66271.12
DVx Inc45.85bn172.91m10.82bn319.0060.461.1417.890.23616.6116.614,394.81880.721.9826.604.02--0.74743.111.777.5710.3911.600.37711.491.51--0.001447.57-3.442.57-81.53-29.2311.2315.81
JMS Co Ltd65.29bn-36.00m13.33bn5.65k--0.32524.740.2042-1.49-1.492,668.181,657.260.82072.784.07---0.05781.33-0.08651.9721.5924.29-0.07051.570.987--0.397943.412.432.38-112.81---2.421.22
OLBA Healthcare Holdings Inc117.02bn1.50bn13.68bn1.32k8.741.2010.780.1169250.44250.4419,539.551,826.782.6616.204.3288,854,800.003.402.7112.139.7811.5811.061.280.91740.9764152.760.162732.162.330.5165-7.896.06-6.4211.84
Techno Medica Co Ltd10.28bn1.35bn15.45bn225.009.720.882521.191.50181.53181.531,319.311,998.920.55772.552.65--7.316.688.787.8050.1048.8613.1112.313.85----39.339.781.9617.154.190.71687.67
Japan Medical Dynamic Marketing, INC.23.18bn1.27bn16.87bn488.0013.190.65765.810.727648.3048.30880.53968.740.76090.68154.15--4.296.514.927.5363.6966.975.638.882.11--0.055218.268.786.74-10.68-8.52-2.959.24
HOSHI IRYO-SANKI CO., LTD14.78bn1.39bn17.37bn470.0011.360.92737.511.18447.23447.234,742.975,478.130.667434.485.35--6.375.668.077.1948.7849.049.558.652.86--0.045815.747.256.4211.159.87-13.238.45
Daiken Medical Co Ltd9.75bn988.60m17.48bn188.0015.952.2514.531.7934.4134.41339.39244.440.88563.914.03--8.987.4412.9110.8440.8441.7410.149.281.58752.550.23171.356.713.0138.843.03-4.010.9806
Seed Co Ltd32.40bn1.96bn17.71bn974.007.601.023.690.546576.9476.941,276.55573.500.72332.657.48--4.381.997.533.5143.7842.316.062.740.8037--0.578139.565.891.90721.4415.3020.424.56
Medius Holdings Co Ltd250.78bn847.94m18.60bn2.29k21.810.93647.160.074238.5138.5111,407.31897.032.2717.994.25109,607,600.000.76731.643.176.0212.0511.490.33810.58370.899338.740.565731.155.497.29-19.8015.0942.529.46
Japan Tissue Engineering Co., Ltd.2.51bn143.17m24.85bn215.00173.594.0989.659.893.533.5361.91149.730.36253.534.26--2.06-4.722.37-5.3167.2457.305.69-16.385.85996.59----23.701.29119.63--30.22--
Data as of May 22 2024. Currency figures normalised to Daiken Medical Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

3.45%Per cent of shares held by top holders
HolderShares% Held
SBI Asset Management Co., Ltd.as of 22 Jul 2022334.00k1.05%
Dimensional Fund Advisors LPas of 09 May 2024227.30k0.71%
Nomura Asset Management Co., Ltd.as of 30 Apr 2024179.40k0.56%
Daiwa Asset Management Co. Ltd.as of 29 Mar 2024107.10k0.34%
Nikko Asset Management Co., Ltd.as of 10 May 202486.80k0.27%
Bessemer Investment Management LLCas of 31 Jan 202451.10k0.16%
Mitsubishi UFJ Asset Management Co., Ltd.as of 10 May 202438.30k0.12%
Norges Bank Investment Managementas of 31 Dec 202329.90k0.09%
BlackRock Japan Co. Ltd.as of 09 May 202426.40k0.08%
Sumitomo Mitsui Trust Asset Management Co., Ltd.as of 20 Apr 202319.30k0.06%
More ▼
Data from 22 Jun 2023 - 16 May 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.